Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan [0.03%]
具有流行或大流行潜力的病毒的再利用药物：地平线扫描
Sola Akinbolade,Rhiannon Potter,Alex Inskip et al.
Sola Akinbolade et al.
Viruses such as Ebola, Marburg, influenza, mpox, MERS-CoV, SARS-CoV, and SARS-CoV-2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time-consuming and resource intensive. Repurposing ...
Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk [0.03%]
DHA和EPA补充剂对心血管结局和房颤风险的荟萃分析
Sepideh Karkon Shayan,Rosull Saadoon Abbood,Sarah F Al-Taie et al.
Sepideh Karkon Shayan et al.
Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. Omega-3 fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been...
Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806 [0.03%]
激活钾通道TREK-1和TREK-2的两种孔结构域 Kv4 通道调节剂NS5806的作用
E L Veale,P M Matthews,A M Rush et al.
E L Veale et al.
NS5806 is a diaryl-urea small molecule developed for the treatment of pain and neurological disorders. A potent activator of Kv4.3 potassium channels, it is widely used to study Kv4 channel physiology in excitable cells, including trigemina...
An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances [0.03%]
日本抗菌药物审评中对外籍临床数据的评估：根据监管情况考虑数据外推时的种族和地区差异
Rumiko Shimazawa,Masayuki Ikeda
Rumiko Shimazawa
The approval requirements in new regions that do not require domestic clinical data and the clinical data evaluation of multi-regional clinical trials (MRCTs) and foreign clinical trials (FCTs) in the Japanese approval review processes for ...
From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice [0.03%]
从试验到临床：将迷幻辅助治疗实施于临床实践中的考量
Jessie Kim,Liam Lochhead,Cory R Weissman
Jessie Kim
Jennifer A Koenig,Steven J Tucker
Jennifer A Koenig
Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat [0.03%]
新型髓过氧化物酶抑制剂米替哌的群体药代动力学特征研究
Mikael Sunnåker,Jacob Leander,Hans Ericsson
Mikael Sunnåker
Mitiperstat is a novel myeloperoxidase inhibitor being investigated for the treatment of heart failure, metabolic dysfunction-associated steatohepatitis, and chronic obstructive pulmonary disease. Pharmacokinetic data from five clinical tri...
The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function [0.03%]
精神药物阿立哌唑诱导膀胱癌细胞毒性的同时保持尿路上皮和膀胱功能
Liam A O&#x;Callaghan,Katie Powell,Russ Chess-Williams et al.
Liam A O&#x;Callaghan et al.
Aripiprazole (ARI), an atypical antipsychotic, has demonstrated anticancer activity in several malignancies and may be a candidate for drug repurposing as an intravesical therapy for bladder cancer, particularly non-muscle-invasive bladder ...
Methods Applied to Assess Real-World Effectiveness of Drugs: A Scoping Review [0.03%]
评估药物真实世界有效性的方法学研究：综合文献回顾
Benedikte Irene von Osmanski,Janne Petersen,Charlotte Thor Petersen et al.
Benedikte Irene von Osmanski et al.
Drug effectiveness evaluations are needed to bridge the gap between premarketing trials and clinical practice, but the specific methods used in such evaluations remain unclear. Therefore, this review aimed to identify pharmacoepidemiologica...
Comparative Sleep Architecture Profiles of Antidepressants in Mice: Pharmacological Characterization of Paroxetine, Sertraline, Duloxetine, Mirtazapine and Vortioxetine [0.03%]
抗抑郁药小鼠睡眠结构的比较表型：帕罗西汀、舍曲林、度洛西丁、米氮平和沃替西汀的药物学特征研究
Junya Maruoka,Ryo Egami,Yuto Akita et al.
Junya Maruoka et al.
Sleep is a biological process essential for various brain functions, and patients with major depressive disorder (MDD) frequently experience sleep disturbances. Since such disturbances are both symptoms and risk factors for depression, eval...
Comparative Study
Pharmacology research & perspectives. 2026 Jun;14(3):e70246. DOI:10.1002/prp2.70246 2026